Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu
Trial record 2 of 3 for:    NSR-REP1

A Safety Study of Retinal Gene Therapy for Choroideremia (GEMINI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03507686
Recruitment Status : Recruiting
First Posted : April 25, 2018
Last Update Posted : August 22, 2019
Information provided by (Responsible Party):
NightstaRx Ltd

Brief Summary:
This is a multi-centre, open-label, prospective, two-period, interventional safety study of bilateral use of AAV2-REP1 in adult male subjects with genetically confirmed CHM.

Condition or disease Intervention/treatment Phase
Choroideremia Drug: AAV2-REP1 Phase 2

Detailed Description:

This is a phase 2 clinical trial of a gene therapy vector made from adenoassociated virus (AAV) called AAV2-REP1 for the treatment of Choroideremia. Participating subjects will be required to attend a screening visit during which their suitability for the study will be assessed, and eligible subjects will undergo a surgical procedure under general anaesthesia consisting of vitrectomy, retinal detachment and sub-retinal administration of AAV2-REP1.

Subjects will be treated bilaterally, with the interval between eyes determined by discussion between the investigator and Nightstar. Participating subjects will be required to attend follow up visits for 12 months following the second eye surgery.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Safety Study of Retinal Gene Therapy for Choroideremia With Bilateral, Sequential Administration of Adeno-Associated Viral Vector (AAV2) Encoding Rab Escort Protein 1 (REP1)
Actual Study Start Date : November 6, 2017
Estimated Primary Completion Date : March 31, 2020
Estimated Study Completion Date : March 31, 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: AAV2-REP1
Bilateral sub-retinal administration of AAV2-REP1 at a range of intervals.
Drug: AAV2-REP1
Sub-retinal injection of AAV2-REP1 after vitrectomy.
Other Name: Gene Therapy

Primary Outcome Measures :
  1. Adverse events as a measure of safety and tolerability [ Time Frame: up to 2 years ]
    Incidence of treatment emergent adverse events (%)

Secondary Outcome Measures :
  1. Best Corrected Visual Acuity [ Time Frame: up to 2 years ]
    ETDRS visual acuity chart

  2. Fundus autofluorescence (AF) [ Time Frame: up to 2 years ]
    Change in AF (mm2)

  3. Optical coherence tomography [ Time Frame: up to 2 years ]
    Ellipsoid Zone

  4. Microperimetry [ Time Frame: up to 2 years ]
    Change in Sensitivity (dB)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Are willing and able to give informed consent for participation in the study to have both eyes treated.
  2. Are male and ≥18 years of age.
  3. Have a genetically-confirmed diagnosis of CHM.
  4. Have active disease clinically visible within the macular region of both eyes.
  5. Have a BCVA within certain visual acuity criteria in both eyes

Exclusion Criteria:

  1. Have a history of amblyopia or inflammatory disorder in either eye.
  2. Are unwilling to use barrier contraception methods, for a period of 3 months following treatment with AAV2-REP1 in either eye.
  3. Have had previous intraocular surgery performed within 3 months of the Screening Visit in either eye
  4. Have any other significant ocular or non-ocular disease/disorder which, in the opinion of the investigator, may either put the subjects at risk because of participation in the study, or may influence the results of the study, or the subject's ability to participate in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03507686

Layout table for location contacts
Contact: Nightstarx Limited +1 866-633-4636

Layout table for location information
United States, Florida
Study Site Recruiting
Miami, Florida, United States, 33136
Sponsors and Collaborators
NightstaRx Ltd

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: NightstaRx Ltd Identifier: NCT03507686    
Other Study ID Numbers: NSR-REP-02
2017-002395-75 ( EudraCT Number )
First Posted: April 25, 2018    Key Record Dates
Last Update Posted: August 22, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by NightstaRx Ltd:
Gene Therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Eye Diseases, Hereditary
Eye Diseases
Choroid Diseases
Uveal Diseases
Genetic Diseases, Inborn
Genetic Diseases, X-Linked